News & Updates

One in five patients with neovascular age-related macular degeneration (nAMD) fail to start treatment within 1 year of presentation, reports a study. Factors associated with lower treatment initiation include Asian race, age <60 years, and low-vision status, among others.

Two phase III induction trials have demonstrated the efficacy and safety of obefazimod, an oral, first-in-class, small molecule, for the treatment of adults with moderate-to-severe ulcerative colitis (UC).